GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzamend Neuro Inc (FRA:9ZT1) » Definitions » EV-to-EBIT

Alzamend Neuro (FRA:9ZT1) EV-to-EBIT : -0.79 (As of Oct. 31, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alzamend Neuro EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alzamend Neuro's Enterprise Value is €5.40 Mil. Alzamend Neuro's EBIT for the trailing twelve months (TTM) ended in Jul. 2024 was €-6.87 Mil. Therefore, Alzamend Neuro's EV-to-EBIT for today is -0.79.

The historical rank and industry rank for Alzamend Neuro's EV-to-EBIT or its related term are showing as below:

FRA:9ZT1' s EV-to-EBIT Range Over the Past 10 Years
Min: -586.84   Med: 0   Max: 0.44
Current: -0.94

During the past 6 years, the highest EV-to-EBIT of Alzamend Neuro was 0.44. The lowest was -586.84. And the median was 0.00.

FRA:9ZT1's EV-to-EBIT is ranked worse than
100% of 419 companies
in the Biotechnology industry
Industry Median: 10.01 vs FRA:9ZT1: -0.94

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Alzamend Neuro's Enterprise Value for the quarter that ended in Jul. 2024 was €0.00 Mil. Alzamend Neuro's EBIT for the trailing twelve months (TTM) ended in Jul. 2024 was €-6.87 Mil. Alzamend Neuro's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jul. 2024 was %.


Alzamend Neuro EV-to-EBIT Historical Data

The historical data trend for Alzamend Neuro's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzamend Neuro EV-to-EBIT Chart

Alzamend Neuro Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
EV-to-EBIT
Get a 7-Day Free Trial - - -6.77 -3.22 -0.48

Alzamend Neuro Quarterly Data
Apr19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.75 -0.73 -0.44 -0.48 -0.26

Competitive Comparison of Alzamend Neuro's EV-to-EBIT

For the Biotechnology subindustry, Alzamend Neuro's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alzamend Neuro's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzamend Neuro's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alzamend Neuro's EV-to-EBIT falls into.



Alzamend Neuro EV-to-EBIT Calculation

Alzamend Neuro's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5.400/-6.869
=-0.79

Alzamend Neuro's current Enterprise Value is €5.40 Mil.
Alzamend Neuro's EBIT for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alzamend Neuro  (FRA:9ZT1) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Alzamend Neuro's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jul. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jul. 2024 ) =EBIT / Enterprise Value (Q: Jul. 2024 )
=-6.869/0
= %

Alzamend Neuro's Enterprise Value for the quarter that ended in Jul. 2024 was €0.00 Mil.
Alzamend Neuro's EBIT for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alzamend Neuro EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Alzamend Neuro's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Alzamend Neuro Business Description

Traded in Other Exchanges
Address
3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Alzamend Neuro Headlines

No Headlines